Developmental analysis of the retinoic acid-inducible RAR-beta 2 promoter in transgenic animals.
Retinoic acid (RA) is a signalling molecule important for pattern formation during development. There are three known types of nuclear receptors for RA in mammals, RAR-alpha, RAR-beta and RAR-gamma, which transduce the RA signal by inducing or repressing the transcription of target genes. Here we describe the developmental expression pattern of the mouse RAR-beta 2 promoter. Independent lines of transgenic animals expressing RAR-beta 2 promoter sequences fused to the E. coli beta-galactosidase gene were examined throughout the course of embryogenesis and found to exhibit reproducible and specific patterns of beta-galactosidase expression in a majority of sites that have been shown previously to contain mRAR-beta transcripts. In the limbs, mRAR-beta 2 promoter activity and mRAR-beta transcripts were both excluded from precartilagenous condensations; interestingly, mRAR-beta 2 promoter activity was observed in the apical ectodermal ridge (AER) where mRAR-beta transcripts could not be detected, while no mRAR-beta 2 promoter activity or mRAR-beta transcripts were associated with the limb region that contains the zone of polarizing activity (ZPA). Analysis of the lacZ expression pattern in embryos from mothers treated with teratogenic doses of RA, indicated that mRAR-beta 2 promoter is selectively induced in a manner suggesting that overexpression of the mRAR-beta 2 isoform is involved in RA-generated malformations. The normal and induced expression pattern of the mRAR-beta 2 promoter suggests several possible roles for mRAR-beta 2 in development of the limbs, as an inhibitor of cartilage formation, in programmed cell death and in the formation of loose connective tissue.
Mendelsohn
C
C
Laboratoire de Génétique Moléculaire des Eucaryotes du CNRS, Institut de Chimie Biologique, Faculté de Médecine, Strasbourg, France.
Ruberte
E
E
LeMeur
M
M
Morriss-Kay
G
G
Chambon
P
P
D000818:Animals; D002352:Carrier Proteins / Q000235:genetics*; D000013:Congenital Abnormalities / Q000235:genetics; D015870:Gene Expression / Q000235:genetics; D005786:Gene Expression Regulation / Q000502:physiology*; D005821:Genetic Techniques; D007763:Lac Operon; D051379:Mice; D008822:Mice, Transgenic / Q000196:embryology / Q000502:physiology*; D011401:Promoter Regions, Genetic / Q000187:drug effects / Q000502:physiology*; D018168:Receptors, Retinoic Acid; D014158:Transcription, Genetic / Q000235:genetics*; D014212:Tretinoin / Q000494:pharmacology; D001616:beta-Galactosidase / Q000032:analysis
D002352:Carrier Proteins; D018168:Receptors, Retinoic Acid; D014212:Tretinoin; D001616:beta-Galactosidase